Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)
China flag China · Delayed Price · Currency is CNY
10.18
-0.22 (-2.12%)
May 20, 2026, 11:34 AM CST

SHE:002399 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
5,3175,3805,1865,4317,0976,318
Other Revenue
98.9198.9194.98-61.9247.33
5,4165,4795,2815,4317,1596,365
Revenue Growth (YoY)
2.15%3.75%-2.77%-24.14%12.48%19.38%
Cost of Revenue
3,6363,7733,5324,4904,8614,367
Gross Profit
1,7801,7061,749940.92,2981,998
Selling, General & Admin
865.91847.8786.751,192975.69850.68
Research & Development
222.6226.16212.04-252.14221.1
Other Operating Expenses
48.9547.2924.6-34.4922.7320.96
Operating Expenses
1,1551,1391,0161,1581,2991,165
Operating Income
624.4567.25732.91-217.29998.55833.53
Interest Expense
-71.44-71.44-141.18-223.22-235.24-201.63
Interest & Investment Income
48.3138.27240.3175.9554.1454.86
Earnings From Equity Investments
----447.95--
Currency Exchange Gain (Loss)
140.6140.6-12.8485.87186.33-205.04
Other Non Operating Income (Expenses)
-263.73-70.18-77.96-30.71-32.55-46.18
EBT Excluding Unusual Items
478.14604.5741.23-757.34971.23435.53
Impairment of Goodwill
----68.16--
Gain (Loss) on Sale of Investments
-33.74-193.2445.6216.2-176.91-226.82
Gain (Loss) on Sale of Assets
0.221.840.72--2.76-5.1
Asset Writedown
-21.38-19.31-55.52-44.52-0.42-1.1
Other Unusual Items
8.448.44-5.83-74.5238.7119.75
Pretax Income
431.68402.24726.23-928.33829.85222.26
Income Tax Expense
57.8459.6101.31-126.18114.82-11.12
Earnings From Continuing Operations
373.84342.64624.92-802.16715.04233.38
Minority Interest in Earnings
6.636.8521.8218.912.397.4
Net Income
380.47349.49646.74-783.26727.43240.79
Net Income to Common
380.47349.49646.74-783.26727.43240.79
Net Income Growth
-41.31%-45.96%--202.10%-76.49%
Shares Outstanding (Basic)
1,4671,4671,4671,4781,4681,467
Shares Outstanding (Diluted)
1,4671,4671,4671,4781,4681,467
Shares Change (YoY)
-0.01%--0.72%0.67%0.05%8.42%
EPS (Basic)
0.260.240.44-0.530.500.16
EPS (Diluted)
0.260.240.44-0.530.500.16
EPS Growth
-41.31%-45.96%--201.95%-78.32%
Free Cash Flow
1,4441,5921,991-39.22-979.03-200.49
Free Cash Flow Per Share
0.981.081.36-0.03-0.67-0.14
Dividend Per Share
0.1450.1450.250-0.1000.035
Dividend Growth
-42.00%-42.00%--185.71%-76.67%
Gross Margin
32.87%31.15%33.11%17.32%32.10%31.39%
Operating Margin
11.53%10.35%13.88%-4.00%13.95%13.10%
Profit Margin
7.03%6.38%12.25%-14.42%10.16%3.78%
Free Cash Flow Margin
26.67%29.05%37.71%-0.72%-13.68%-3.15%
EBITDA
950.83887.891,030105.611,2721,103
EBITDA Margin
17.56%16.20%19.51%1.94%17.77%17.34%
D&A For EBITDA
326.43320.64297.46322.89273.87269.92
EBIT
624.4567.25732.91-217.29998.55833.53
EBIT Margin
11.53%10.35%13.88%-4.00%13.95%13.10%
Effective Tax Rate
13.40%14.82%13.95%-13.84%-
Revenue as Reported
5,4795,4795,281-7,1596,365
Advertising Expenses
-25.926.18-23.218.04
Source: S&P Global Market Intelligence. Standard template. Financial Sources.